million, X. down Thank Ashland you, Please to quarter were turn morning, the to everyone. good year. in prior Total XX% Slide Guillermo, and compared sales $XXX
dynamics Continued These inflation last our segments. carried business volume continued customer within by recovery, from declines growth partially and which reduced has all resulted for destocking pharmaceutical over sales volumes were in offset year.
impact a sales. negligible Foreign currency had on
Gross to be primarily slower destocking. to ran the sales we lower to plants driven segments lower XX.X%, by in since due our customer across margin declined with volumes line absorption,
levels. As by These profit gross the number the a million. intentional impacted products for we a negatively consequence customer continued of inventory of goods we actions approximately saw finished order destocking production throughout slowed to control own quarter, $XX our in
key in expectations items costs and million, million for SG&A, in lower the EBITDA late from quarter $XXX from was the largely prior June. accruals. million down and year were Ashland’s excluding When in incentive $XXX line XX% adjusted intangible million, the reflecting year prior with R&D compensation $XXX $XXX amortization in our down and In total,
discussed. year, quarter the again prior adjusted XX% I the was EBITDA for XX.X%, just the factors down in Ashland’s margin reflecting from
Adjusted inventory our down acquisition improvement a stemming million from and quarter, year lower changes amortization $XX free quarter flow the cash prior actions was XX% Ongoing share, the the quarter. working per year, reflecting sales. from EPS, internal control significant capital for was from prior excluding for primarily the in $X.XX
Within well, operating being the sales a each review year mid-single-digit period. four Sciences, our down business Please pharmaceutical up volumes for solid strong to delivered mix turn X. segments. Life of prior pricing compared results our to growth, held let’s was Slide despite Now, and
took and sales levels mix control to EBITDA pharma challenged inventory nutraceuticals X% strong EBITDA nutrition We impacting areas approximately continued nutraceuticals. to quarter, results by to reflecting The Overall, nutrition sales appropriate EBITDA due X% and Adjusted declined by remained weaker Sciences actions businesses margin while margin million. $XXX adjusted to to to by $X meaningfully Life million. million, customer increased due like destocking. increased during enhanced in and low nearly XX%, the segment $XX
to Slide XX. turn Please
Care negatively in quarter. destocking impacted customer Continued Personal the
For our to the volumes Sales care actions impacted Personal modestly customer meaningfully markets to year. lower Care were to quarter, XX% negatively EBITDA impacted to by Sales sales XX% more a but million, while a and inventory declined were adjusted the market sales continues by margins by control bright by million. with driven destocking, oral hair proactive actions. declined Pricing care $XXX $XX were to destocking skin the negative and compared only prior mix. care down into spot, hold, the
Specialty felt the primarily to Additives reduced continued XX. turn Please versus related to prior impact destocking. Pricing customer year. quarter demand, the also of in remained Slide positive
to the performance as impacted primarily team proactive construction and coatings, quarter. actions as However, destocking by $X volume in nearly profitability the of million declines specialties, due negatively in well inventory control
the declined $XX by to Specialty $XXX quarter, Additives million. to declined For million, XX% sales EBITDA while by adjusted XX%
while of of about reported and year NMP, value nearly the destocking to and Please down Internal sales sales THF pricing accounted decline, XX% XX% $XX were remaining the by sales of turn year-over-year prior our sales driven XX. million, BLO market of higher merchant decline. customer volumes. year-over-year for to lower the solvents XX% captive compared Slide Intermediates including
performance this margin pricing raw contributed high than which revenue, Although, the value a part offset in party in quarter. declines delinking solvents continued third BDO, business strong very to of tailwinds, more our small material from our represents of the
year Intermediates adjusted a and to reported of prior XX.X%. EBITDA decrease million, to declined margin adjusted EBITDA XX% compared $XX of
Please turn to Slide XX.
in authorization, replaced reported June, billion late existing authorization. Board we a of $X Directors As new share evergreen the Ashland’s repurchase which approved
share this million fiscal of $XXX previous repurchases completed year. the during had under Ashland authorization
of liquidity $XXX had June quarter on As about of billion. $X.X of total hand XX, million on the roughly available with close cash we
which was about debt X.X turns leverage. million, of net is Our $XXX
We debt the style of years, have all debt floating debt next for is terms. no and outstanding no to outstanding, subject credit our X investment-grade rate long-term maturities
enhanced coatings. pursue our growth M&A targeted strategy businesses on of care and We investing to organically grow in opportunities our through continue personal are existing profitable and pharma, to focused bolt-on
with a as as and with continued pursue well to balance share global policy Against dividend a repurchase. flexibility strong of has sheet shareholders a backdrop targeted strategy uncertainty, growth strong our reward our Ashland the
that, for outlook With our I’ll year fiscal discuss turn to the over Guillermo? back to Guillermo XXXX. call